“E-selectin inhibition as GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Transplantation for Multiple Myeloma”  
Zachary Crees, M.D.  
Mentors: Keith Stockerl-Goldstein, M.D., Geoffrey Uy, M.D., and John DiPersio, M.D., Ph.D.

“Phase I Trial of Trastuzumab Deruxtecan and Neratinib in Solid Tumors with HER2 Alterations”  
Whitney Hensing, M.D.  
Mentors: Haeseong Park, M.D., M.P.H., Cynthia Ma, M.D., Ph.D., and Ron Boxe, M.D., Ph.D.

“A Phase I/II Trial of CA-4948 in Combination with FOLFOX ± bevacizumab for Untreated Metastatic Colorectal Cancer”  
Michael Iglesia, M.D., Ph.D.  
Mentor: Katrina Pedersen, M.D.

“A Prospective Study of the Implementation of Whole Genome Sequencing for Genetic Subtyping of Diffuse Large B Cell Lymphoma”  
David Russler-Germain, M.D., Ph.D.  
Mentors: Eric Duncavage, M.D., David Spencer, M.D., Ph.D., Todd Fehniger, M.D., Ph.D.

“A Phase II Study of Liposomal irinotecan (Nal-IRI) in Combination with Pembrolizumab (Pembro) for Triple-Negative Breast Cancer (TNBC) with Brain Metastases (BM)”  
Jing Xi, M.D., M.P.H.  
Mentors: Jian Campian, M.D., Ph.D., Cynthia Ma, M.D., Ph.D.

“Prospective Study of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)”  
Alice Zhou, M.D., Ph.D.  
Mentor: Armin Ghobadi, M.D.

Opening Remarks: 5:45pm

John Welch, M.D., Ph.D. – Associate Director for Basic Science and Career Development
Oral Presentations: 5:50pm – 8:30pm

5:50pm “Phase II Trial with Safety Lead in of Duvelisib Maintenance after Autologous Stem Cell Transplant in T-cell and Indolent B-cell Lymphomas”
Mary-Kate Malecek, M.D
Mentor: Amanda Cashen, M.D.

6:10pm “A Phase Ib Clinical Trial of Cabozantinib and Abiraterone with Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)”
Dhruv Bansal, M.B.B.S.
Mentor: Russell Pachynski, M.D., Ph.D.

6:30pm “Severity of Cytokine release syndrome influences outcomes after axicabtagene Ciloleucel for large B cell lymphoma: Results from the US CAR T consortium”
Miriam Jacobs, M.D.
Mentor: Armin Ghobadi, M.D.

6:50pm “Prediction Models and Remote-Health Monitoring to Reduce Readmissions for Patients with Cancer”
Gradon Nielsen, M.D.
Mentor: Olivia Aranha, M.D., Ph.D.

7:10pm “A Randomized Phase II trial of Cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma”
Vanessa Eulo, M.D.
Mentor: Brian Van Tine, M.D., Ph.D.

7:30pm “A Phase I/II Trial of Pre-emptive Therapy with Oral Decitabine to Improve Outcomes in MDS Patients with Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant”
Ryan Day, M.D., Ph.D.
Mentor: Meagan Jacoby, M.D., Ph.D.

7:50pm “A Phase I Study with an Expansion Cohort of duvelisib and nivolumab in mycosis fungoides (MF) and Sézary syndrome (SS)”
Lauren Shea, M.D.
Mentor: Neha Mehta-Shah, M.D.

8:10pm “A Phase I/II Trial of Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma”
Scott Goldsmith, M.D.
Mentor: Ravi Vij, M.B.B.S.

Closing Remarks: 8:30pm

Saiama Waqar, M.B.B.S. – Program Director